期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利巴韦林治疗丙型肝炎出现贫血的应对措施 被引量：3

暂未订购
导出
摘要 利巴韦林联合干扰素治疗慢性丙型病毒性肝炎始于1998年。单用普通干扰素（IFN）治疗丙型肝炎的持续病毒应答（SVR）仅16%,而加用利巴韦林治疗后SVR提高到41%[1]。另有报道[2-3],单用聚乙二醇干扰素（PegIFN）SVR为18%-39%,而联合利巴韦林后的SVR上升至54%-56%。
作者 罗生强
机构地区 解放军三○二医院中西医结合肝病中心二科
出处 《肝脏》 2011年第1期71-72,共2页 Chinese Hepatology
关键词 利巴韦林 丙型肝炎 治疗 慢性丙型病毒性肝炎 聚乙二醇干扰素 贫血 持续病毒应答 联合干扰素
分类号 R512.63 [医药卫生—内科学]
  • 相关文献

参考文献16

  • 1McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med, 1998,339: 1485-1492.
  • 2Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002,347 : 975-982.
  • 3Zeuzem S, Feinman SV,Rasenack J, et al. Evaluation of the safety and efficacy of once-weekly peg/interferon alfa-2a (PEGASYSTM) for chronic hepatitis C. A multinational, randomized study [ abstract GS2/08 ]. J Hepatol, 2000, 32(Suppl2) :29.
  • 4De Franchesi LD, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology, 2000,31 : 997-1004.
  • 5Reau N, Jensen D, Hadziyannis S, et al. Early predictors of anemia in patients with HCV genotype 1 treated with peginterferon alfa-2a (40 KD) plus ribavirin 1000-1200 rag/day. Am J Gastroenterol, 2008,103 : 1981-1988.
  • 6Jacobson IM, Freilieh B, Afdhal N, et al. Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): Final results of the WlN-R Study, a US community based trial [abstract 72446]. Presented at 56th annual meeting of the American Association for the Study of Liver Diseases; November 11-15, 2005; SanFrancisco, CA.
  • 7Martin LM, Younossi ZM, Price LL, et al. The impact of ribavirin-induced anemia on health-related quality of life [abstract 600A]. Presented at 56th annual meeting of the American Association for the Study of laver Diseases; November 11-15, 2005; San Francisco, CA.
  • 8Salmeron J, DiagoM, Andrade R, et al. Induction doses of interferon alpha 2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non responders to interferon monotherapy: a randomized trial. JViralHepat,2007,14(2) :89-95.
  • 9Kawaguchi Y, Mizuta T, Takahashi K, et al: High-dose vitamins E and C supplementation prevents ribavirin-indueed hemolytic anemia in patients with chronic hepatitis C. Hepatol Res, 2007,37 (5) ;317-324.
  • 10Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol, 2003,98:2491-2499.

同被引文献33

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量：732
  • 2Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: all update. Hepatology, 2009, 49: 1335-1374.
  • 3Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 2002,347 : 975-982.
  • 4Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associaited with high-dose interferon a-2b therapy. J Clin Oncol,2002,20:3703- 3718.
  • 5Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology, 2(1(}3, 124 1711-1719.
  • 6Mchutchison JG, Lawitz EJ, Shiffman ML, et al. Peg interferon a- 2b or a-2a with Ribavirin for treatment of Hepatitis C infection. N Engl J Med, 2009,361 : 580-591.
  • 7Kawaguchi Y, Mizuta T, Takahashi K,et al: High-dose vitamins E and C supplementation prevents ribavirin induced hemolytic anemia in patients with chronic hepatitis C. Hepatol Res, 2007, 37: 317- 324.
  • 8Falasca K, Ucciferri C, Maneino P, et al. Use of epoetin beta during combination therapy of infection with hepatitis C virus with ribavirin improves a sustained viral response. J Med Virol,2010, 82:49-56.
  • 9Watanake U. The risk factor for development of thyroid disease during interferon therapy for chronic hepatitis C. Gastroenterol 1994,89 399-403.
  • 10Cozzolongo R,Betterle C, Fabris P, et al. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur .I Gastroenterol Hepatol,2006,18 : 689.

引证文献3

二级引证文献7

肝脏
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部